Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm Female|Stage I Breast Cancer|Stage II Breast Cancer|Hormone Receptor Negative Neoplasm|Hormone Receptor Positive Tumor
Interventions: DRUG: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Sponsor: Institut Català d'Oncologia
Collaborators: Amgen